Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

A clinical-stage biopharma developing cell and gene therapies for orthopedic diseases.

950160 | KO

Overview

Corporate Details

ISIN(s):
KR8840120008
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-03-27 00:00
주식등의대량보유상황보고서(일반)
Korean 96.3 KB
2024-03-26 00:00
전환청구권행사 (제1회차)
Korean 10.0 KB
2024-03-20 00:00
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구) (손해배상청구)
Korean 13.9 KB
2024-03-20 00:00
감사보고서제출
Korean 20.0 KB
2024-03-20 00:00
사업보고서 (2023.12)
Korean 1.2 MB
2024-03-20 00:00
소속부변경
Korean 3.6 KB
2024-03-19 00:00
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.9 KB
2024-03-13 00:00
주주총회소집결의
Korean 9.0 KB
2024-03-13 00:00
주주총회소집공고
Korean 153.1 KB
2024-02-14 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 16.3 KB
2023-12-18 00:00
투자판단관련주요경영사항(임상시험계획승인신청등결정)(TG-C의 척추질환 적응증에 대한 FDA 제1상 임상시험계획신청(IND) 승인)
Korean 12.3 KB
2023-12-13 00:00
기타경영사항(자율공시)(제25기 정기주주총회 권리주주 확정을 위한 증권예탁증권(KDR) 기준일 설정 공고)
Korean 5.1 KB
2023-11-16 00:00
투자판단관련주요경영사항(임상시험계획승인신청)(TG-C의 척추질환 적응증에 대한 FDA 제1상 임상시험계획승인신청(IND))
Korean 9.7 KB
2023-11-14 00:00
분기보고서 (2023.09)
Korean 1.1 MB
2023-08-14 00:00
반기보고서 (2023.06)
Korean 1.0 MB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kolon TissueGene, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.